Our results support that the concomitant treatment of DZNeP and Ven causes more inhibition of proliferation and induces synergistic cell death in AML compared to monotherapies not only in cell lines, but also in AML primary blasts with the expansion of c-KIT, which suggests that c-KIT may be recognized as a specific biomarker which has a promising response to this dual-suppressed BCL-2 and EZH2 blockade by Ven and DZNeP. This evidence concerns the gene EZH2 and acute myeloid leukemia.